Rong Li

US Patent:

20110305668, Dec 15, 2011

Filed:

Aug 14, 2009

Appl. No.:

13/058359

Inventors:

Rong Li - Rockville MD, US
Sheldon S. Miller - Bethesda MD, US
Arvydas Maminishkis - Washington DC, US

Assignee:

The United States of America, as represented by the Secretary, Dept.of Health and Human Services - Rockville MD

International Classification:

A61K 38/21
A61P 27/06
A61P 27/02

US Classification:

424 855

Abstract:

Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.

US Patent:

20230130372, Apr 27, 2023

Filed:

Dec 17, 2020

Appl. No.:

17/757510

Inventors:

- Austin TX, US
- Washington DC, US
Hui DENG - Houston TX, US
Xiujie SUN - Washington DC, US
Rong LI - Washington DC, US

International Classification:

C07K 16/28
C12N 15/63
A61P 35/00

Abstract:

The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.

US Patent:

20170176440, Jun 22, 2017

Filed:

Mar 26, 2015

Appl. No.:

15/129597

Inventors:

Rong LI - San Antonio TX, US
Bin YUAN - San Antonio TX, US
Qinong YE - Beijing, CN
Long CHENG - Beijing, CN

Assignee:

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

G01N 33/574
C07K 16/28

Abstract:

Embodiments are directed to methods of evaluating the prognosis of a breast cancer patient by assessing the level of phosphorylation tyrosine 36 of estrogen receptor beta (ERB). Certain embodiments are directed to methods for evaluating the prognosis of a cancer patient comprising contacting a breast cancer sample from a patient with stage II or stage III breast cancer with an antibody that binds phosphorylated tyrosine 36 of Eiβ; quantifying phosphorylation of tyrosine 36 of EIβ; and classifying the patient as having a good prognosis if phosphorylated tyrosine 36 levels are elevated or classifying the patient as having a poor prognosis if tyrosine levels are decreased relative to a non-cancer control. Certain embodiments are directed to an antibody or antibodies that specifically bind tyrosine 36 (Y36) of the ERp.